Abstract:Abstract BACKGROUND Glioblastoma (GBM) is the most common malignant primary adult brain tumor, characterized by extensive cellular and genetic heterogeneity. The Standard of Care (SOC) therapy and clinical trials have not been successful in improving patients’ survival which underscores an urgent need for developing new effective therapies for this treatment refractory disease. MATERIAL AND METHODS In silico and in vitro analysis have revealed high level of Fibroblast Activation Protein (FAP) expression in GBM tissue in multiple cell populations including endothelial cells, fibroblasts, stromal cells and tumor cells, but not on normal brain tissue, making FAP a safe and suitable therapeutic target as it allows for destruction of tumor cells as well as effective elimination of their supporting microenvironment. As Chimeric antigen receptor (CAR) expressing T cells have shown promising results against multiple cancers in the past few years, we aimed to target FAP in GBM by FAP specific CAR-T cells generated using a novel GMP-ready FAP-CAR construct produced based on a virus-free CAR gene transfer using advanced sleeping beauty transposon technology and preclinically test their anti-tumor efficacy against GBM at in vitro and in vivo level. RESULTS Our data revealed that co-culturing CAR-T cells with FAP+ GBM cells (U87) results in increased surface expression of T-cell activation markers. Moreover, FAP CAR-T mediated cytotoxicity against FAP+ GBM cells was also observed in the co-culture of GBM and CAR-T cells. For further validation, the effect of FAP CAR-T cells will be tested on patient-derived GBM organoids. The in vivo efficacy of FAP CAR-T cells is currently under investigation and we anticipate that the treatment of GBM tumor-bearing mice with FAP CAR-Ts results in extended survival and reductions of tumor burden. CONCLUSION These rigorously obtained data show high level of efficacy for FAP-specific CAR-T cells against GBM suggesting that clinical development of this therapeutic modality can provide a novel therapeutic strategy for GBM patients that can be used in combination with SOC or other immunotherapeutics. Therefore, upon successful completion of the preclinical study, we plan to conduct a phase I dose-escalation trial of autologous FAP-CAR T cells for patients with recurrent Glioblastoma.

Tracking tumor alteration in glioma through serum fibroblast activation protein combined with image

Oncogenesis, Microenvironment Modulation and Clinical Potentiality of FAP in Glioblastoma: Lessons Learned from Other Solid Tumors

Noninvasive imaging of FAP expression using positron emission tomography: A comparative evaluation of a [18F]-labeled glycopeptide-containing FAPI with [18F]FAPI-42

In vitro and in vivo evaluation of 211At-labeled fibroblast activation protein inhibitor for glioma treatment

Circulating tumor cell is a common property of brain glioma and promotes the monitoring system

Evaluation of serum extracellular vesicles as noninvasive diagnostic markers of glioma

Circulating Tumor Cells for Glioma

Serum GFAP Autoantibody As an ELISA-detectable Glioma Marker

Biom-72. Integration Of Ultrasensitive Electroluminescent Immunoassay And Cell-Free Dnamethylation Analysis For Non-Invasive Monitoring Of Adult Diffuse Gliomas

Rapid tumor detection via a fibroblast activation protein-alpha activated fluorogenic probe

ELISA Based Serum Glial Fibnillary Acidic Protein Autoantibody Detection and Its Application in Glioblastoma Diagnosis

Serum Protein Fingerprinting Coupled with Artificial Neural Network Distinguishes Glioma from Healthy Population or Brain Benign Tumor

P06.15.B IMMUNOTHERAPEUTIC TARGETING OF FIBROBLAST ACTIVATION PROTEIN (FAP) IN TREATMENT REFRACTORY GLIOBLASTOMA USING NOVEL CAR-T CELL THERAPY

Circulating Biomarkers for Tumour Monitoring, Prognosis Predictions and Detection of Temozolomide Resistance Mutations in Glioma

Serum Neurofilament Light, Glial Fibrillary Acidic Protein and Tau Are Possible Serum Biomarkers for Activity of Brain Metastases and Gliomas

Serum protein fingerprinting coupled with artificial neural network distinguishes glioma from healthy population and brain benign tumo

The Fibronectin Expression Determines the Distinct Progressions of Malignant Gliomas via Transforming Growth Factor-Beta Pathway

68Ga-FAPI-04 PET/CT in Non-Small Cell Lung Cancer: Accurate Evaluation of Lymph Node Metastasis and Correlation with Fibroblast Activation Protein Expression

Protein typing of circulating microvesicles allows real-time monitoring of glioblastoma therapy

Serum levels of GFAP and EGFR in primary and recurrent high-grade gliomas: correlation to tumor volume, molecular markers, and progression-free survival

From basic research to clinical application: targeting fibroblast activation protein for cancer diagnosis and treatment